Effect of Pre-injection of Rocuronium on Neuromuscular Blockade Onset Time and Hemodynamics During General Anesthesia Induction

Condition(s) studied

Investigational drug(s) / intervention(s)

Rocuronium Bromide (Pretreatment Injection): Low-dose rocuronium bromide is injected intravenously in advance before anesthesia induction

Rocuronium Bromide (Conventional Injection): Rocuronium bromide is administered by standard routine intravenous injection during anesthesia induction

Study summary

This is a single-center, prospective, randomized, controlled trial comparing pre-injection versus standard bolus administration of rocuronium bromide for general anesthesia induction. A total of 108 adult patients (18-65 years, ASA I-III) scheduled for elective surgery requiring endotracheal intubation will be enrolled and randomized 1:1 to either the pre-injection group or control group.

The pre-injection group will receive rocuronium 0.06 mg/kg as a priming dose followed by 0.54 mg/kg 3 minutes later. The control group will receive rocuronium 0.6 mg/kg as a single bolus. All patients will receive standardized anesthesia induction with midazolam and propofol.

The primary outcome is neuromuscular blockade onset time (seconds). Secondary outcomes include hemodynamic parameters (SBP, DBP, MAP, HR, CO, SV, SVR), injection pain incidence, and adverse events.

This study aims to investigate whether pre-injection of rocuronium can shorten neuromuscular blockade onset time while maintaining hemodynamic stability compared to standard bolus administration.

Eligibility

Primary outcome measure(s)

• Neuromuscular blockade onset time — Within 5 minutes after completion of rocuronium-bromide injection
  The time interval from injection of rocuronium bromide to maximum neuromuscular block effect

Trial sites (1)

More General Hospital of Ningxia Medical University trials in China

Other trials for the same condition